Pediatrix Medical Group, Inc. (MD)

Pediatrix Medical Group Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	8	73.26	9.82	387.39	1,124	107.87
Short-Term Investments	107.47	104.49	93.24	99.72	104.87	74.51
Cash & Cash Equivalents	115.47	177.74	103.06	487.11	1,229	182.38
Cash Growth	12.29%	72.46%	-78.84%	-60.36%	573.71%	170.54%
Receivables	283.75	272.31	296.79	301.78	241.93	434.27
Other Current Assets	27.3	33.4	28.14	51.68	78.7	114.86
Total Current Assets	426.52	483.45	427.99	840.56	1,549	731.51
Property, Plant & Equipment	144.62	145.93	140.21	135.62	132.16	129.09
Goodwill and Intangibles	1,412	1,405	1,551	1,527	1,505	1,508
Other Long-Term Assets	185.02	185.02	229.1	219.37	161.83	1,777
Total Long-Term Assets	1,742	1,736	1,920	1,882	1,799	3,414
Total Assets	2,168	2,220	2,348	2,723	3,348	4,146
Accounts Payable	207.04	350.8	374.23	394.12	423.18	410.64
Current Debt	37.44	35.99	36.49	22.17	21.15	18.25
Other Current Liabilities	2.8	2.16	16.27	11.07	0	112.93
Total Current Liabilities	247.28	388.95	426.98	427.37	444.34	541.82
Long-Term Debt	741.22	665.66	680.59	1,044	1,784	1,775
Other Long-Term Liabilities	323.47	316.14	348.68	354.83	372.34	330.21
Total Long-Term Liabilities	1,065	981.8	1,029	1,398	2,156	2,105
Total Liabilities	1,312	1,371	1,456	1,826	2,600	2,647
Total Debt	778.66	701.65	717.08	1,066	1,805	1,793
Debt Growth	-5.36%	-2.15%	-32.72%	-40.94%	0.65%	-9.19%
Retained Earnings	-145.44	-149.47	-89.06	-155.39	-286.35	510.13
Comprehensive Income	-2.15	-2.21	-3.74	1.32	3.53	0.08
Shareholders' Equity	856.2	849.06	891.63	896.49	747.49	1,499
Net Cash / Debt	-663.19	-523.91	-614.02	-578.72	-576	-1,610.76
Net Cash Per Share	-7.96	-6.37	-7.30	-6.74	-6.91	-19.17
Working Capital	179.24	94.51	1.01	413.2	1,105	189.69
Book Value Per Share	10.33	10.33	10.68	10.57	8.96	17.95

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).